Adriana M Kakehasi
Overview
Explore the profile of Adriana M Kakehasi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
131
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rubbert-Roth A, Kakehasi A, Takeuchi T, Schmalzing M, Palac H, Coombs D, et al.
Rheumatol Ther
. 2023 Nov;
11(1):97-112.
PMID: 37982966
Introduction: This article aims to describe malignancies in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), or non-radiographic axial spondyloarthritis (nr-axSpA) treated with upadacitinib (UPA) or active...
2.
Bredemeier M, Duarte A, Pinheiro M, Kahlow B, Macieira J, Ranza R, et al.
Rheumatology (Oxford)
. 2023 May;
63(2):456-465.
PMID: 37216912
Objectives: To test the association of use of antimalarials with the overall safety of treatment in RA patients receiving one or multiple courses of biologic (b)DMARDs or a Janus kinase...
3.
Lopes Marques C, Ribeiro S, Albuquerque C, de Sousa Studart S, Ranzolin A, de Andrade N, et al.
Adv Rheumatol
. 2022 Nov;
62(1):45.
PMID: 36419163
Objectives: To evaluate the disease activity before and after COVID-19 and risk factors associated with outcomes, including hospitalization, intensive care unit (ICU) admission, mechanical ventilation (MV) and death in patients...
4.
Carvalho J, Dos Reis Neto E, Kakehasi A, Ribeiro S, Studart S, Martins F, et al.
Lupus
. 2022 Oct;
32(1):42-53.
PMID: 36300790
Objectives: To evaluate factors associated with COVID-19 severity outcomes in patients with systemic lupus erythematosus (SLE). Methods: This was a cross-sectional analysis of baseline data of a prospective, multi-stage cohort...
5.
Bredemeier M, Ranza R, Kakehasi A, Ranzolin A, da Silveira I, Ribeiro A, et al.
J Rheumatol
. 2022 Jan;
49(1):122.
PMID: 34974425
No abstract available.
6.
Vieira Rezende R, Braz A, Guimaraes M, Ribeiro S, Abreu Vieira R, Bica B, et al.
Vaccine
. 2021 Oct;
39(44):6454-6459.
PMID: 34600751
Objectives: To identify potential predictors of COVID-19 vaccine hesitancy (C19-VH) in adults with immune-mediated inflammatory diseases (IMID). Methods: A total of 1000 IMID patients were enrolled in this web-based cross-sectional...
7.
Moraes F, da Silva M, Dos Santos J, Acurcio F, Almeida A, Kakehasi A, et al.
Value Health Reg Issues
. 2021 Aug;
26:135-141.
PMID: 34390960
Objectives: To assess the quality of life (QOL) and its associated factors in patients with psoriatic arthritis (PsA) who would start treatment with biologic drugs at the Brazilian Unified Health...
8.
Pinheiro M, Pileggi G, Kakehasi A, Gomides Reis A, Reis-Neto E, Abreu M, et al.
Clin Exp Rheumatol
. 2021 Jul;
40(7):1258-1266.
PMID: 34251312
Objectives: To evaluate the incidence of COVID-19 and its main outcomes in rheumatic disease (RD) patients on hydroxychloroquine (HCQ) compared to household cohabitants (HC). Methods: This is a 24-week nationwide...
9.
Bredemeier M, Ranza R, Kakehasi A, Ranzolin A, da Silveira I, Ribeiro A, et al.
J Rheumatol
. 2021 May;
48(10):1519-1527.
PMID: 33934077
Objective: To evaluate the safety of the methotrexate (MTX)-leflunomide (LEF) combination in rheumatoid arthritis (RA), comparing it with other therapeutic schemes involving conventional synthetic (cs-) and biologic (b-) disease-modifying antirheumatic...
10.
Machado C, Resende G, Macedo R, do Nascimento V, Branco A, Kakehasi A, et al.
Clin Exp Rheumatol
. 2019 Jan;
37(2):306-309.
PMID: 30620271
Objectives: The objective of the study was to compare the production of metalloproteinases (MMP)-1, -3 and interleukin (IL)-6 by fibroblast-like synoviocytes (FLS) derived from synovial fluid (FD-FLS), and FLS derived...